Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33

Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578

Bristol-Myers and Ono Pharmaceutical announced an agreement that grants Bristol-Myers Squibb an exclusive license for the development and commercialization of ONO-4578, Ono's selective Prostaglandin E2 receptor 4 antagonist. The companies will also collaborate on discovery efforts to identify additional compounds from Ono's PGE2 receptor antagonist programs. Under the terms of the agreement, Bristol-Myers Squibb will make an upfront payment of $40M to Ono. Bristol-Myers Squibb will be solely responsible for the development, manufacturing and commercialization of ONO-4578 as well as other PGE2 receptor antagonist products in all countries of the world except Japan, South Korea, Taiwan, China and Association of Southeast Asian Nations countries. Ono is eligible to receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties in these countries where Bristol-Myers Squibb has exclusive license. In Japan, South Korea and Taiwan, Bristol-Myers Squibb and Ono will partner on the development and commercialization under the companies' existing collaboration agreement, while in China and ASEAN countries, Ono will retain exclusive rights.

  • 18

    Jan

  • 05

    Mar

BMY Bristol-Myers
$63.47

0.19 (0.30%)

11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

, STRA

Strayer

$92.18

-0.64 (-0.69%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Strayer to host special shareholder meeting »

Special shareholder…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

STRA

Strayer

$92.18

-0.64 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

EXEL

Exelixis

$27.86

0.37 (1.35%)

, IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Exelixis and Ipsen co-host a financial community briefing »

Exelixis and Ipsen…

EXEL

Exelixis

$27.86

0.37 (1.35%)

IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

OCUL

Ocular Therapeutix

$5.54

-0.02 (-0.36%)

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Upgrade
Ocular Therapeutix rating change  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Conference/Events
Federal Reserve Bank of Atlanta President speaks at breakfast meeting »

Federal Reserve Bank of…

IBM

IBM

$169.12

0.47 (0.28%)

08:23
01/19/18
01/19
08:23
01/19/18
08:23
Recommendations
IBM analyst commentary  »

IBM price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:22
01/19/18
01/19
08:22
01/19/18
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$203.27

0.12 (0.06%)

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$67.67

0.12 (0.18%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.48

-0.63 (-0.82%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$104.69

-0.09 (-0.09%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

$83.06

0.08 (0.10%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Conference/Events
Lincoln National to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

XLB

S&P Select Materials SPDR

$62.90

-0.04 (-0.06%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$50.14

-0.32 (-0.63%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$57.39

-0.17 (-0.30%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$88.11

0.02 (0.02%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$17.02

-0.25 (-1.45%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Initiation
Switch initiated  »

Switch initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$156.54

-1.08 (-0.69%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$260.16

-0.92 (-0.35%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLPN

Dolphin Entertainment

$3.15

-0.1 (-3.08%)

08:17
01/19/18
01/19
08:17
01/19/18
08:17
Initiation
Dolphin Entertainment initiated  »

Dolphin Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.